FDA’s Vinay Prasad, controversial CBER chief, to depart
WASHINGTON — Vinay Prasad, a prime official on the Food and Drug Administration who has been on the heart of recurring public controversies, is exiting the company for a second time.
Prasad will go away the FDA on the finish of April, and his substitute has not but been recognized, FDA Commissioner Marty Makary told The Wall Street Journal.
An FDA spokesperson confirmed Prasad’s departure. Prasad did not instantly reply to requests for remark from STAT.
His departure comes after a sequence of controversial company choices on uncommon illness medicine by the Center of Biological Evaluation and Research, which Prasad oversees. It additionally comes a day after the Health and Human Services Department, which oversees the FDA, held a press call during which a senior official tried an experimental Huntington’s therapy — an unconventional step involving dialogue of a remedy being thought of by regulators.
Prasad, an oncologist by coaching who was additionally serving because the FDA’s chief scientific and medical officer, oversaw the regulation of vaccines, gene therapies, and blood merchandise. Under his management, CBER has elevated scrutiny of uncommon illness medicine on the similar time Makary and others have been publicly stressing regulatory flexibility.
Prasad’s heart has not too long ago rejected a minimum of 5 cell and gene therapies that consultants consider probably may have acquired approval underneath earlier FDA officers.
In some instances, drugmakers have accused the company of reversing itself earlier agreements on medical trial designs. A drug to deal with a uncommon blood most cancers, for instance, was on the trail to FDA approval final 12 months earlier than the company rejected it final month, based mostly on considerations about medical information that the corporate thought had been beforehand addressed.
The choices have spooked rare disease patient advocateswho’ve questioned whether or not the company’s rhetoric on embracing flexibility for uncommon illness medicine matches up with its actions.
Prasad took over as CBER director in May of 2025, however was fired in July after he angry uncommon illness group advocates and far-right influencer Laura Loomer, who’s shut to President Trump, along with his dealing with of a therapy for Duchenne muscular dystrophy. The administration changed course just some weeks later, nevertheless, and employed him again after Makary vouched for him.
He didn’t return humbled, STAT beforehand reported. One of his first strikes upon returning was to fireplace the particular person in command of vaccine security and surveillance, putting in himself as a substitute. Prasad has pushed a minimum of seven leaders out of their positions. Eight company officers advised STAT in October that Prasad had created a piece setting that was rife with mistrust and paranoia.
During his tenure, Prasad, as a key ally of Makary’s, performed a key position in among the company’s most necessary initiatives. He led the committee charged with evaluating drug submissions bestowed with a “Commissioner’s National Priority Voucher,” which ensures a regulatory resolution inside one to two months. The position allowed him to weigh in on drug choices exterior his purview as CBER director.
He additionally sought to maintain vaccines to a regulatory stage that, in accordance to 12 former FDA commissioners, might make it impossible for producers to develop new merchandise. Prasad and prime drug regulator Tracy Beth Høeg have wrested control of surveillance vaccine from profession employees. Most not too long ago, Prasad overruled staff by refusing to overview a brand new flu vaccine from Moderna. The company ultimately agreed to overview the product after White House pressure.
The FDA and different well being businesses have taken a extra vaccine-skeptical strategy underneath well being secretary Robert F. Kennedy Jr., a recognized vaccine critic.
Prasad, who lives in California, labored on the FDA’s Silver Spring, Md., campus just some days every week. Still, employees members mentioned he sought an uncommon diploma of management over employees from afar, requiring them to make their calendars completely visible to him regardless of his personal calendar remaining personal. He advised employees not to notify their supervisors if he requested conferences with them.
Four officers advised STAT on the time that a number of staff had filed complaints about Prasad’s administration fashion with human assets.
This is a growing story and will probably be up to date.
